Cohort Study of the Clinical Course of Macular Diseases in Japanese

Sponsor
Kyoto University, Graduate School of Medicine
Study ID
NCT02081339
Status
Unknown

Conditions

  • Macular Disease

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Key Dates

Start date
Mar 31, 2014
Status verified
Sep 2016
Primary completion
Mar 31, 2022
Completion
Mar 31, 2024

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Macular diseases
    ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡

Primary Outcome Measure

Initial factors associated with visual prognosis in each macular disease [ Time Frame: Five years after the registration ]

Central Contacts

Related Studies